Pharmaceutical companies routinely cross borders: licensing a compound to a European partner, running a multinational clinical trial, manufacturing API in India, distributing finished product in Brazil. Each of these international transactions requires a carefully drafted agreement that addresses both US and foreign law requirements, intellectual property protection across jurisdictions, and regulatory compliance obligations that vary by country. A pharma company that uses its standard domestic agreements for international transactions without modification is taking on risks that may not become apparent until an IP enforcement action fails in a foreign court or a regulatory inspection surfaces a compliance gap.

This guide covers the governing law and jurisdiction issues in international pharma agreements, how EU pharmaceutical regulations affect cross-border contracts, international IP protection strategies for pharma licensing, and the key provisions in a cross-border pharmaceutical license agreement. At Lopes Law LLC, Anthony Lopes, Esq. is fluent in English, Spanish, and Portuguese (native), providing unique capability for transactions involving Latin American and Lusophone pharmaceutical partners.

What Governing Law and Jurisdiction Issues Arise in International Pharma Agreements?

The governing law provision in an international pharma agreement determines which country’s law applies to interpreting and enforcing the contract. The dispute resolution provision determines where and how disputes are resolved. Both provisions require careful consideration in international pharma transactions.

Choice of Governing Law

The most common governing law choices for international pharma agreements are: New York law (preferred by US companies; New York has extensive commercial contract precedent and predictable outcomes), Delaware law (common for US biotech and pharma companies with Delaware incorporation), English law (widely used for international commercial transactions, particularly in European pharma deals), and Swiss law (preferred for its neutrality and confidentiality protections in international transactions involving European parties).

The governing law affects: how contract terms are interpreted when the language is ambiguous, what implied obligations apply (e.g., implied covenant of good faith), what damages are available for breach, and how IP assignment provisions are construed. For cross-border pharma agreements with parties in Brazil, Portuguese law or New York law (with arbitration) are common choices depending on the sophistication of the parties.

Dispute Resolution: Arbitration vs. Local Courts

International pharma companies strongly prefer arbitration over local court litigation for cross-border disputes. The reasons are practical: (1) arbitral awards are enforceable in 172 countries under the New York Convention; (2) arbitration provides confidentiality that court proceedings do not; (3) arbitration allows the parties to select arbitrators with pharma industry expertise; (4) local court proceedings in many countries are unpredictable for foreign pharmaceutical companies, particularly in IP enforcement contexts.

Common arbitration rules for international pharma disputes: ICC (International Chamber of Commerce, Paris), LCIA (London Court of International Arbitration), AAA-ICDR (International Centre for Dispute Resolution, New York), and SIAC (Singapore International Arbitration Centre, preferred for Asian pharma transactions). The seat of arbitration and the language of proceedings should be specified in the agreement.

IP Enforcement Varies by Jurisdiction

A US patent does not provide protection in Europe or Asia. A PCT application filed under the Patent Cooperation Treaty provides an initial 18-month protection period and a prior art search report, but national-phase filings are still required in each country or region where protection is sought. An international pharma license agreement must address which party is responsible for filing and maintaining patent protection in each territory, and who bears the cost of those filings.

How Do EU Pharmaceutical Regulations Affect International Contracts?

The EU pharmaceutical regulatory framework is distinct from the US FDA framework in several important ways that must be addressed in cross-border pharma agreements. Failing to address EU-specific requirements in contracts with European partners creates compliance gaps that can affect both regulatory approvals and commercial relationships.

EU GMP and Technical Agreements

EU GMP requirements under EudraLex Volume 4 apply to pharmaceutical manufacturing in Europe. All contract manufacturing in Europe requires a written Technical Agreement (TA) between the marketing authorization holder and the CMO, which is the EU equivalent of a Quality Agreement. The TA must address: the responsibilities of each party for GMP compliance, the role of the Qualified Person (QP) in batch release, handling of regulatory inspections by EMA or national competent authorities, and out-of-specification (OOS) investigation procedures.

EMA Regulatory Data Exclusivity

The EU provides 10 years of data exclusivity for innovative medicines (8 years of data protection plus 2 years of market exclusivity, extendable by 1 year for a new therapeutic indication). This is a separate IP right from patent protection. A license agreement for EU territories must address which party owns the EU marketing authorization and has the benefit of the data exclusivity period. Data exclusivity prevents generic companies from relying on the originator’s clinical data for their own EU marketing authorization applications during the protection period.

GDPR for Clinical Data from EU Participants

Clinical trial data from EU participants is GDPR-protected personal data. International pharma agreements involving EU clinical trial data must include GDPR-compliant provisions: a Data Processing Agreement (DPA) where one party processes personal data on behalf of another, Standard Contractual Clauses (SCCs) for transfers of personal data from EU to the US (unless the US entity is certified under the EU-US Data Privacy Framework), and provisions addressing the rights of EU data subjects. Health data is special category data under GDPR Article 9 and requires either explicit consent of the data subject or another specifically enumerated legal basis for processing.

EU MDR for Combination Products

Combination products (drug-device combinations) must comply with both EU pharmaceutical regulation and EU MDR (Medical Device Regulation 2017/745). International agreements involving combination products must address the regulatory pathway in each territory and allocate responsibility for EU MDR compliance, which includes notified body oversight, clinical evaluation requirements, and post-market surveillance obligations.

What IP Protection Strategies Are Used in International Pharma Licensing?

IP protection across multiple jurisdictions requires a coordinated strategy that combines patent filings, trade secret protection, and contractual controls. No single mechanism provides complete protection in all relevant markets.

PCT (Patent Cooperation Treaty) Filing

A PCT application, filed under the Patent Cooperation Treaty administered by WIPO, provides: (1) a unified filing date as the priority date in 157 contracting states; (2) an international search report from a qualified searching authority within 16 months; and (3) an 18-month window from the priority date to decide which national phases to enter before incurring the cost of individual national filings. For international pharma licensing, the PCT application is the foundation of the patent filing strategy: it establishes the priority date globally before the compound is publicly disclosed in a licensing discussion.

Supplementary Protection Certificates (SPCs) in the EU

An SPC extends patent protection for pharmaceutical products in each EU member state by the time lost between the date of the patent application and the date of the first EU marketing authorization, up to a maximum of 5 years (5.5 years with a pediatric extension). SPCs are country-specific and must be applied for in each EU member state where protection is desired. International license agreements covering EU territories should address who is responsible for pursuing SPCs and who bears the cost of SPC applications and maintenance.

Territory Restrictions in License Agreements

Territory restrictions in international pharma license agreements define the geographic scope of the license. Exclusive licenses for specific territories are the norm in pharma licensing: the licensee receives exclusive rights in the licensed territory and agrees to develop and commercialize the product in that territory. The license agreement must clearly define: which countries are included in the territory, whether the territory is exclusive or non-exclusive, what happens if the licensee fails to obtain regulatory approval in specific countries within the territory, and whether the territory can be reduced (terminated for a specific country) if the licensee fails to meet diligence obligations in that country.

What Are the Key Provisions in a Cross-Border Pharmaceutical License Agreement?

An international pharma license agreement combines the standard license agreement provisions with international-specific requirements that affect IP protection, royalty calculation, regulatory responsibility, and termination rights.

Licensed IP Definition

The licensed IP must be precisely defined: which patent families are included (with a schedule of all patent numbers and application numbers in each territory), whether manufacturing know-how and trade secrets are licensed, whether the data package (clinical study reports, regulatory dossier) is included, and whether the license includes improvements to the licensed compound developed after the agreement date.

Regulatory Responsibility Allocation

The license agreement must specify which party files for regulatory approval in each territory and who owns the resulting marketing authorization. Options include: (1) the licensor retains the marketing authorization and the licensee commercializes under the licensor’s authorization; (2) the licensee obtains its own marketing authorization using the licensor’s data; (3) the licensee obtains authorization and the licensor has a license-back right. Each structure has different implications for regulatory data ownership, post-marketing commitments, and what happens to the marketing authorization if the license agreement terminates.

Net Sales Definition and Permitted Deductions

Royalties in international pharma license agreements are typically calculated as a percentage of “Net Sales.” The net sales definition determines which deductions from gross sales are permitted before calculating the royalty base. Permitted deductions typically include: trade discounts and rebates, returns and allowances, sales taxes and customs duties, distribution fees, and government price adjustments. In EU markets, mandatory government rebates (reference pricing, payback schemes) can be substantial and must be addressed in the net sales definition.

Milestone Payment Structure

Development milestones in international agreements are typically tied to regulatory events in specific territories: US IND approval, US Phase 2 completion, EU clinical trial authorization, EU marketing authorization application, US FDA approval, EU EMA approval, and first commercial sale in each major territory. The milestone payments and their trigger events must be carefully defined to avoid disputes about whether a regulatory event in one country triggers a milestone payment obligation.

Client Scenario: The Royalty Calculation Dispute

A US biotech licensed its compound to a European pharma company for the EU territory. The license agreement specified royalties of 8 percent on “Net Sales” in the EU territory, with permitted deductions including “government-mandated rebates and price adjustments.” The net sales definition was drafted primarily with the US market in mind and did not specifically address the EU’s mandatory payback schemes, reference pricing systems, or the specific deductions permitted under the German and French reimbursement frameworks.

When European commercial sales began, the European pharma company calculated net sales by deducting all mandatory government rebates under each EU country’s national pricing system. The total deductions in Germany and France alone reduced gross sales by approximately 22 percent before any other deductions. The US biotech expected a much smaller deduction based on its US-market understanding of “government-mandated rebates.”

The resulting dispute required arbitration in London to resolve the correct calculation methodology. The lesson: international pharma license agreements must specifically address EU-specific pricing and reimbursement deductions, ideally with country-specific schedules defining the permitted deduction categories. At Lopes Law LLC, we advise clients entering EU licensing transactions to address this issue with specificity before the agreement is signed, not in arbitration afterward.

What Are the Key Considerations for Cross-Border Agreements with Brazilian Partners?

Brazil is one of the largest pharmaceutical markets in the world and a major destination for US and European pharma companies seeking international partnerships. Cross-border pharma agreements with Brazilian partners have specific considerations that differ from EU and US-focused transactions.

ANVISA Regulatory Requirements

ANVISA (Agencia Nacional de Vigilancia Sanitaria) is Brazil’s federal health regulatory agency with authority over pharmaceutical registration, clinical trial authorization, and import permits. Cross-border pharma agreements with Brazilian partners must address ANVISA registration requirements, who is responsible for obtaining and maintaining ANVISA approval, and the timelines and costs of the ANVISA registration process. ANVISA’s requirements for importing clinical trial investigational products are distinct from FDA requirements.

IP Enforcement in Brazil

Brazil is a signatory to the TRIPS Agreement and provides patent protection for pharmaceutical compounds. However, Brazilian IP enforcement through local courts can be slower than in the US or EU. International pharma agreements with Brazilian parties should include international arbitration provisions to avoid dependence on local court enforcement. The CAMARB (Brazil-Canada Chamber of Commerce) and FIESP arbitration chambers are commonly used for Brazilian commercial disputes.

At Lopes Law LLC, Anthony Lopes, Esq. is a native Portuguese speaker with direct experience in cross-border pharmaceutical contract review. For US pharma companies entering Brazilian partnerships, we provide bilingual contract review that identifies legal-conceptual differences between US and Brazilian contract law, not just translation accuracy. International pharma NDA and CDA review is $1,500 to $2,000 flat fee. More complex licensing and distribution agreements are quoted based on scope after a free consultation.

For pharma NDA considerations relevant to international agreements, see our post on Pharmaceutical NDAs: What Biotech and Pharma Companies Need to Know. For cross-border NDA and CDA agreements specifically, see our guide on Cross-Border NDA and CDA Agreements. For GDPR compliance considerations in clinical data transfers, see our post on GDPR Compliance for US Businesses.

Reach out, we are friendly. Call now for a free consultation at (267) 777-9117 or schedule your free 20-minute consultation online.